Adaptive Biotechnologies Corp (ADPT) stock
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$28.05−0.41 (-1.44%)
Close on Nov 19, 2026Market cap $4.48BP/E –Yield –
Adaptive Biotechnologies free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Adaptive Biotechnologies's free cash flow for the twelve months ending Jun 30, 2026 was -$24.03M. For fiscal 2025 it was -$48.95M. The highest annual figure on record is $194.20M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$48.95M | – |
| FY2024 | Dec 31, 2024 | -$98.88M | – |
| FY2023 | Dec 31, 2023 | -$167.02M | – |
| FY2022 | Dec 31, 2022 | -$200.29M | – |
| FY2021 | Dec 31, 2021 | -$254.47M | – |
| FY2020 | Dec 31, 2020 | -$168.49M | -186.8% |
| FY2019 | Dec 31, 2019 | $194.20M | – |
| FY2018 | Dec 31, 2018 | -$38.56M | – |
| FY2017 | Dec 31, 2017 | -$37.28M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.58M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.33M | – |
| Q4 FY2025 | Dec 31, 2025 | $1.42M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.54M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.09M | – |
| Q1 FY2025 | Mar 31, 2025 | -$29.74M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.57M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.41M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.03M | – |
| Q1 FY2024 | Mar 31, 2024 | -$39.86M | – |
| Q4 FY2023 | Dec 31, 2023 | -$28.23M | – |
| Q3 FY2023 | Sep 30, 2023 | -$49.46M | – |
| Q2 FY2023 | Jun 30, 2023 | -$27.25M | – |
| Q1 FY2023 | Mar 31, 2023 | -$62.08M | – |
| Q4 FY2022 | Dec 31, 2022 | -$32.56M | – |
| Q3 FY2022 | Sep 30, 2022 | -$47.84M | – |
| Q2 FY2022 | Jun 30, 2022 | -$52.36M | – |
| Q1 FY2022 | Mar 31, 2022 | -$67.53M | – |
| Q4 FY2021 | Dec 31, 2021 | -$63.07M | – |
| Q3 FY2021 | Sep 30, 2021 | -$58.06M | – |
| Q2 FY2021 | Jun 30, 2021 | -$59.25M | – |
| Q1 FY2021 | Mar 31, 2021 | -$74.09M | – |
| Q4 FY2020 | Dec 31, 2020 | -$49.21M | – |
| Q3 FY2020 | Sep 30, 2020 | -$51.36M | – |
| Q2 FY2020 | Jun 30, 2020 | -$33.34M | – |
| Q1 FY2020 | Mar 31, 2020 | -$34.57M | -112.6% |
| Q4 FY2019 | Dec 31, 2019 | -$29.21M | – |
| Q3 FY2019 | Sep 30, 2019 | -$33.57M | – |
| Q2 FY2019 | Jun 30, 2019 | -$17.49M | – |
| Q1 FY2019 | Mar 31, 2019 | $274.47M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.91M | – |
| Q3 FY2018 | Sep 30, 2018 | -$13.88M | – |
See a number that looks wrong?